Avacta Group PLC - biotherapeutics company - Enters into an agreement with Abingdon Health for the manufacture of its saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity. Avacta, in partnership with Cytiva, is developing a rapid test strip for use with patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the SARS-CoV-2 coronavirus. Avacta says Abingdon Health's two sites in York and Doncaster, UK are able to produce millions of rapid tests per month. Technology transfer to Abingdon Health will begin immediately with the aim of manufacturing an equivalent rapid antigen test product which therefore does not require additional clinical validation/regulatory approvals. The agreement with Abingdon Health will provide additional manufacturing capacity that could increase to several millions of tests per month.
Current stock price: 157.15 pence
Year-to-date change: multiplied
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Avacta Group (AVCT)